IDEA AG concludes Licence Agreement for its innovative targeted analgesic, Diractin®, with Alpharma
This release was saved as a PDF file. Please click on the "view PDF" link to display this report.
You need the free Adobe Reader in order to display this release.Download Adobe Reader
IDEA is a privately held biopharmaceutical company with headquarters in Munich, Germany. IDEA develops and commercialises non-invasive, targeted therapeutics, applied through the skin. The proprietary carriers are typically applied on skin and can be engineered to achieve high drug concentration at or near the site of application, diminish local or systemic adverse side effects, and often increase drug potency. In total, close to 60 patents from 9 patent families are currently protecting the core technology. The Company’s leading products are in the area of dermatology and pain. IDEA-033, with blockbuster potential in the peripheral pain market, is approaching the end of its Phase III clinical development programme in Europe. Regulatory submission to EMEA is currently expected in Q1 2007 and possibly within the following 12 months in USA.. IDEA’s in-house capabilities range from formulation and small-scale (GMP) manufacturing work to clinical testing. For further information see IDEA’s website at www.idea-ag.de.